Speed, Quality and Cost – Leveraging Australia to Expedite Clinical Development
In recent years, the pharmaceutical industry has seen tremendous changes in the way it is...
Predicting the future of cancer immunotherapy: Using autoantibody biomarkers to drive safer and more...
For a number of years now, immunotherapy has been seen as the dawn of a...
KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant...
KemPharm, Inc. , a specialty pharmaceutical company focused on the discovery and development of proprietary...
PANTHERx Specialty Pharmacy and RxCrossroads by McKesson Collaborate to Streamline the Channel for Precision...
PANTHERx® Specialty Pharmacy, The Rare Disease Specialty Pharmacy , and RxCrossroads by McKesson, the leading...
Medigene AG: Medigene Signs Exclusive License Agreement with Leiden University to Develop Novel T...
Medigene AG announced that it has entered into an exclusive license agreement with Leiden University...
RetiPharma Secures Funding to Develop Treatments of Degenerative Eye Disorders
RetiPharma, focusing on the development of products for the treatment of degenerative eye disorders based...
Sygnature Discovery announces multi target drug discovery deal with Sitryx Therapeutics
Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, has announced a...
Proprietary Nasal Delivery Formulation of Diazepam Developed by Particle Sciences’ Reaches NDA
Proprietary nasal delivery formulation of diazepam for the treatment of epilepsy developed by CDMO, Particle...
Celerion Expands NASH Biomarkers Services With the Implementation of FibroScan
Celerion, a leader in early clinical research, is pleased to announce the implementation of FibroScan®...
AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program
AbbVie ,a research-based global biopharmaceutical company, announced that it will assume full development and commercial...